| PFE |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$0.69 vs. cons $0.678 |
MEDIUM |
| PFE |
Report |
Total revenue |
IN-LINE |
pred ~$14.50B vs. cons $14.379B |
MEDIUM |
| PFE |
Report |
Vyndaqel revenue |
MISS |
pred ~$1.68B vs. cons $1.702B |
MEDIUM |
| PFE |
Guide |
FY26 revenue |
LOWER |
guide $59.5B-$62.5B vs. cons $61.761B |
MEDIUM |
| PFE |
Guide |
FY26 adjusted diluted EPS |
LOWER |
guide $2.80-$3.00 vs. cons $2.939 |
MEDIUM |
| PFE |
Guide |
2H26 COVID / cost commentary |
UNCHANGED |
reiterate seasonal COVID caution and savings trajectory; consensus UNVERIFIED |
LOW |
| PFE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| PFE |
Return |
5-day cumulative residual |
-2.0% (FADE) |
FADE — maintained guidance below consensus should restrain revisions |
LOW |